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Abstract
Background—Healthcare providers have little population-based evidence about health-related
quality of life (HRQOL) changes, from the pre- to post-diagnosis period, and treatment-related
recovery time for women ages 65 and older diagnosed with breast cancer.
Methods—Older women with and without breast cancer completed self-reports of HRQOL at
baseline and 2 years later as part of annual Medicare Health Outcomes Surveys (MHOS). MHOS
was linked to Surveillance, Epidemiology, and End Results registries, which were used to
categorize women with breast cancer by treatment type (breast-conserving surgery, breast-
conserving+radiation, mastectomy) and time since diagnosis at follow-up. Each cancer case
diagnosed in 1998-2007 (N=542) was matched to five women without cancer (N=2,710) using
propensity score matching. Analysis of covariance models examined changes in HRQOL,
adjusting for demographics and initial functioning.
Results—Older women within 6 months of diagnosis had greater declines than women without
cancer in SF-36 Physical (-5.8 vs. -1.8) and Mental (-3.6 vs. -0.7) Component Summary scores,
General Health (-12.3 vs. -4.6), Vitality (-11.0 vs. -2.2), Bodily Pain (-8.5 vs. -2.1), Social
Functioning (-15.1 vs. -3.3), Role-Physical (-26.5 vs. -3.9), and Role-Emotional (-13.1 vs. -3.1)
scores (all p<.05). By approximately 1 year, women with and without breast cancer had similar
HRQOL. Comparable declines in Physical Component Summary and Role-Physical occurred
across treatment types.
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Conclusion—Women ages 65 and older diagnosed with breast cancer should be counseled that
survivors within six months of diagnosis are vulnerable to HRQOL declines, compared to women
without breast cancer, but that decrements generally wane after 12 months.
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Introduction
There is growing emphasis on post-treatment health-related quality of life (HRQOL) for
women ages 65 and older with breast cancer. However, population-based evidence is limited
because older women are systematically underrepresented in breast cancer clinical trials, and
observational and cohort studies focusing exclusively on older breast cancer survivors are
rare.1 Older women have a 6-fold higher incidence rate for breast cancer than younger
women,2 yet little is known about how HRQOL changes from before to after a breast cancer
diagnosis and the duration of treatment-related HRQOL recovery time in this older
population. Projections for the years 2020 and 2030 indicate that the proportion of women
diagnosed at ages 65 and older will increase by 33% and 56%, respectively,3 which
underscores the need for prospective HRQOL studies.
At diagnosis, women are presented with a range of treatment options. Important
considerations in the choice of treatment(s) include HRQOL, comorbid conditions, and life
expectancy (e.g., a 65-year-old woman has an average life expectancy of 20 years). Older
women with breast cancer (OWBC) are a heterogeneous population with varying levels of
functioning and, thus, treatment choice cannot be made on the basis of age alone.4,5
However, healthcare providers have little population-based evidence to counsel OWBC
about changes to expect in HRQOL and how long it will take to recover from different
treatment options, beyond overall survival and recurrence rates. This leaves OWBC in an
uncertain position for making an informed decision about treatment(s) to pursue.
To our knowledge, two population-based studies have focused exclusively on OWBC to
examine prospective HRQOL changes over the first year after diagnosis for OWBC
receiving different treatments.6-7 Ganz et al. conducted a prospective study with 691 OWBC
in four U.S. regions to examine HRQOL at 3, 6 (mental health only), and 15 months post-
diagnosis.6 Treatment categories included breast-conserving surgery (BCS), breast-
conserving surgery+radiation therapy (BCS+RT), mastectomy, and adjuvant chemotherapy
and endocrine therapy.6 Significant predictors of a decline in physical function were greater
comorbid conditions and Medicaid insurance.6 The proportion of OWBC recovering in
HRQOL scores by the 15-month assessment was not reported, and thus, treatment-related
recovery time could not be examined.6
Prescott et al. randomized 255 OWBC at 53 centers in the U.K. to BCS or BCS+RT.7
HRQOL was a primary endpoint assessed at baseline (post-surgery), 2 weeks, 9 months, and
15 months; and similar HRQOL changes were observed for BCS and BCS+RT groups.
Physical functioning was significantly lower at 9 and 15 months for both groups.7 Social
functioning and breast symptoms improved for both groups by 9 months.7 Mobility and
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home maintenance improved by 15 months for both groups and other domains did not
change significantly.7 Both the Ganz and Prescott studies6-7 did not have HRQOL
assessments available prior to cancer diagnosis, which limits the ability to predict the
OWBC who should be targeted for rehabilitation or other supportive care services. Both
studies6-7 also did not have a control group of older women without breast cancer that would
allow assessment of the impact of cancer against age- or comorbidity-related changes in
HRQOL.
We examined the duration of treatment-related HRQOL recovery time and the extent to
which treatment modality affected changes in HRQOL, from the pre- to post-diagnosis
period, among women ages 65 years and older. We also compared older survivors' HRQOL
changes over a 2-year interval to matched older women without cancer.
Methods
Dataset
Clinical data from Surveillance, Epidemiology, and End Results (SEER) cancer registries
were linked to HRQOL data from the Medicare Health Outcomes Survey (MHOS).8-9 The
MHOS is administered annually to approximately 1,000-1,200 randomly selected
beneficiaries from participating managed care organizations in the Medicare Advantage
program (including institutionalized and disabled beneficiaries). Each year (starting in
1998), a baseline survey is administered along with a follow-up survey two years later if the
beneficiary remains in the same managed care organization.9 Eight SEER-MHOS cohorts
are included in this study (1998-2007).
Participants
The SEER-MHOS dataset includes 11,794 beneficiaries with breast cancer and 819,886
without cancer. Individuals with the following characteristics were excluded: men; <65
years old; living outside a SEER catchment area; and did not complete a follow-up MHOS
(Figure 1). For OWBC, further exclusions included: cancer was not diagnosed between at
least one baseline and follow-up MHOS; prior cancer other than breast; missing radiation or
surgery status; second non-breast cancer diagnosis between baseline and follow-up;
unknown disease stage status; and metastatic disease. Propensity score matching methods10
were used to match each breast cancer case (N=542) to 5 women without cancer (N=2,710)
based on demographics (age, race/ethnicity, education, marital status, smoking status),
whether a proxy filled out the baseline survey, type of pre-existing comorbid conditions
(e.g., heart disease, diabetes, etc.), SEER catchment area, and cohort year (Table 1).
Propensity score matching variables were chosen based on literature with OWBC showing
correlations between these variables and HRQOL outcomes2,11 and clinical expertise. For
women without breast cancer who may have participated in more than one MHOS cohort
(thus having multiple baseline and follow-up surveys), we used a random number generator
to pick which records would be retained.
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HRQOL was measured using the RAND Short Form-36 (SF-36)12 for all MHOS through
2005. The SF-36 has been used extensively in individuals with and without cancer.12 The 8
scales of the SF-36 (Physical Functioning, Role-Physical, Bodily Pain, General Health,
Vitality, Mental Health, Role-Emotional, Social Functioning) along with two summary
scores, Physical Component Summary (PCS) and Mental Component Summary (MCS),
were evaluated.
In 2006, the MHOS switched from the SF-36 to the Veterans Rand-12 (VR-12), which
affected the follow-up data for cohorts 7-8. The follow-up scores for 77 women with breast
cancer (14%) and 362 women without breast cancer (13%) were affected by the VR-12
switch. The VR-12 mirrors the same 8 subscales from the SF-36 but with fewer items.
Subscale scores from the SF-36/VR-12 were rescaled so that every response option had a
value in the range of 0-100 (i.e., the lowest score possible is 0 and the highest possible score
is 100) and then averaging items within each subscale.13 This allows items with different
response options to be directly comparable. In order to harmonize across questionnaire
versions, published algorithms were used to derive VR-12 PCS and MCS scores for all
cohorts.14 Population norms for the PCS and MCS scores are reported using 1990 U.S.
norms14 and scored on a T-score metric (mean=50, SD=10). No population-based reference
norms are available for the VR-12 subscale scores.14 Higher SF-36/VR-12 scores reflect
better HRQOL.12
Surgery type was categorized as breast-conserving surgery or mastectomy, according to
SEER guidelines.15 Radiation therapy was dichotomized as yes/no. We created a combined
variable capturing surgery type and radiation status: breast-conserving surgery alone (BCS),
breast-conserving surgery+radiation therapy (BCS+RT), or mastectomy to reflect categories
used by Ganz6 and Prescott.7 Most mastectomy cases (165/188 or 88%) did not receive
radiation. Given the small sample size that would have resulted for a mastectomy+RT
category (n=23), we created one category for mastectomy with or without radiation. We did
a sensitivity analysis excluding the 23 women from the mastectomy group who received RT
and all results remained the same (data not shown).
Analysis Strategy
Analysis of covariance models were used to examine changes in HRQOL controlling for
initial HRQOL and covariates (age, ethnicity/race, marital status, education, smoking status,
SEER catchment area, baseline comorbid conditions, and comorbidities diagnosed between
baseline and follow-up MHOS). SEER variables were also included as covariates in
analyses involving only survivors: breast cancer stage and age at diagnosis.
We first compared changes in HRQOL, from before to after diagnosis, stratified by
treatment type and compared OWBC's changes to women without cancer. We then
categorized OWBC as being 0-6, 7-12, 13-18, or 19+ months post-diagnosis at the time of
MHOS follow-up (because breast cancer was required to be diagnosed between baseline and
follow-up). HRQOL changes were compared between OWBC categorized by time since
diagnosis (regardless of treatment type) and women without breast cancer.
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Analyses were performed in SAS (version 9.3) with two-sided statistical tests. IRB
exemption was granted from the University of North Carolina at Chapel Hill.
Results
Participant Characteristics
Demographic characteristics are provided in Table 1 and clinical characteristics for OWBC
are provided in Table 2. Half of the OWBC were ages 65-74 at the time of diagnosis (52%)
with the remainder diagnosed at ≥75 years. Most OWBC were early stage (79%), Caucasian
(77%), and completed ≤ high school (62%). Matched women without cancer were selected
to reflect similar characteristics.
Missing Data
Given our inclusion criteria requiring both a baseline and follow-up MHOS, missing data
were minimal. For demographics, missing data ranged from education (2%) to proxy filling
out form (8%); ≤ 5% and <1% were missing for comorbidities and SF-36/VR-12 subscales,
respectively. Consistent with standards for missing data, we did not impute data and used
Complete Case Analysis.16
HRQOL Changes by Cancer Status and Time since Diagnosis
OWBC who were within 6 months of cancer diagnosis at follow-up had significantly worse
decline than women without cancer in PCS (-5.8 vs. -1.8), MCS (-3.6 vs. -.07), General
Health (-12.3 vs. -4.6), Bodily Pain (-8.5 vs. -2.1), Vitality (-11.0 vs. -2.2), Social
Functioning (-15.1 vs. -3.3), Role-Physical (-26.5 vs. -3.9), and Role-Emotional (-13.1 vs.
-3.1) scores (all p<.05) (Figure 2 a-d). OWBC and women without cancer did not show
differences in subscale scores for Physical Functioning (-4.9 vs. -1.8) and Mental Health
(-4.6 vs. -1.0) (Figure 2 b-c). With notable exceptions, by approximately 7-12 months after
diagnosis no differences in HRQOL were observed between women with and without breast
cancer.
Vitality, Role-Physical, and General Health scores for OWBC were slower to recover to the
levels of women without breast cancer. At 7-12 months, OWBC remained significantly
lower than women without cancer in Vitality (-6.7 vs. -2.3) and Role-Physical (-14.1 vs.
-3.8) scores (both p<.05), which subsided by 13-18 months post-diagnosis (Figure 2 c-d).
General Health for OWBC was significantly lower at 13-18 months post-diagnosis (-8.4 vs.
-4.5, p<.05) (but not at 7-12 months) (Figure 2 b).
HRQOL Changes by Cancer Status and Treatment Modality
OWBC, across all treatment types, had greater declines over 2 years than women without
breast cancer in PCS (-3.4 vs. -1.8) and Role-Physical (-12.6 vs. -3.8) scores (both p<.05)
(Figure 3 a, d). Women with and without breast cancer did not differ in changes on the MCS
(-1.5 vs. -0.7), Physical Functioning (-7.2 vs. -5.5), Mental Health (-3.0 vs. -1.0), Social
Functioning (-5.6 vs. -3.3), or Role-Emotional (-4.2 vs. -3.4) scores (Figure 3 a-d). OWBC
receiving BCS+RT had greater declines than women without cancer in General Health (-8.9
vs. −4.5) and Vitality (-7.5 vs. -2.3) (both p<.05) (Figure 3 b-c). OWBC receiving a
Stover et al. Page 5






















mastectomy (with or without RT) also showed greater declines in General Health (-9.3 vs.
-4.5) and Vitality (-6.3 vs. -2.3) than women without cancer (both p<.05; Figure 3 b-c).
Head-to-head HRQOL comparisons between OWBC receiving BCS, BCS+RT, or
mastectomy were not significantly different from one another in PCS (-3.2 vs. −3.3 vs. -3.5),
MCS (-1.8 vs. −1.2 vs. −1.6), or subscale scores (Figure 3 a-d), indicating that similar
HRQOL decrements occurred across treatment types.
Discussion
This study quantifies the effects of breast cancer and its treatments on HRQOL for women
ages 65 years and older in comparison with similar women without cancer. Our results
identify the domains of HRQOL most acutely affected by breast cancer and corresponding
recovery time in order to facilitate age-appropriate, early supportive efforts. Inclusion of a
matched control group allowed us to assess the unique impact of breast cancer, controlling
for age- and comorbidity-related changes in HRQOL.
OWBC within 6 months of diagnosis had greater declines than women without cancer in
Physical and Mental Component Summary scores and six out of eight subscales (General
Health, Vitality, Bodily Pain, Social Functioning, Role-Physical, and Role-Emotional). We
observed recovery by 7-12 months in most domains, but slower recovery in Vitality, Role-
Physical, and General Health. In other words, HRQOL declines among OWBC generally
resolved and returned to the same levels as women without breast cancer around 1 year post-
diagnosis.
OWBC's experiences of slower recovery time in Vitality, Role-Physical, and General Health
may be due to radiation or endocrine therapy, chemotherapy, or other unmeasured variables
(e.g., reduced physical activity17). Ionizing radiation may cause damage to normal and
malignant cells and side effects generally occur from damage to normal tissue, which likely
affects HRQOL. Loss of vitality (i.e., fatigue) is a common symptom experienced shortly
after completing radiation therapy.11,17 Our study shows that OWBC continue to experience
greater declines in Vitality and General Health 1-2 years after receiving radiation therapy
than women without cancer. However, omission of radiation therapy is controversial for
OWBC.5
Endocrine therapy may have also played a role in slower recovery times in Vitality, Role-
Physical, and General Health. In a large trial with OWBC, women randomized to an
aromatase inhibitor (after five years on tamoxifen) reported worse HRQOL scores in
vitality, pain, and physical functioning after 12 months compared to OWBC receiving
placebo.18 Endocrine therapy data are not available in SEER,8-9 but 76% of OWBC in our
study had hormone-receptor-positive tumors, which are clinically indicated for adjuvant
endocrine therapy.5 The proportion of hormone-receptor-positive tumors was spread evenly
across treatment types (75% BCS, 72% BCS+RT, 81% mastectomy), suggesting that
influence on our results would have been diffused across groups. However, this diffusion
may partially explain why we did not observe HRQOL differences across treatment types.
More research is warranted with OWBC to determine the effects of endocrine therapy on
HRQOL changes and recovery time.
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Chemotherapy may have played a part in slower recovery times but we were not able to
examine this in our dataset. Chemotherapy data, although available in SEER, are believed to
be unreliable due to limited follow-up and a modest correlation with chart reviews for
women with breast cancer.19 OWBC are considered for chemotherapy when tumors are
grade 3, hormone-receptor-negative with her2 overexpression, or ≥4 nodes are positive.5
Approximately 15-20% of our sample would have been considered for chemotherapy with
these guidelines so we controlled for stage in analyses. The optimal duration of
chemotherapy is not known for OWBC,5 but regimens generally last between 12-24 weeks
(at least 4 cycles). Very little data exist about HRQOL declines from chemotherapy in
OWBC.11,20 Twenty-one percent of the Ganz study participants received chemotherapy and
no significant differences were found in comparison to surgery types, radiation, and
tamoxifen.6 This suggests that the lack of chemotherapy data did not have a large impact on
our results.
When treating OWBC, careful attention to the management of treatment-related symptoms
and comorbid conditions is warranted, especially during the first 6 months after diagnosis. In
turn, enhanced symptom monitoring may shorten recovery time to usual functioning. A
comprehensive geriatric assessment instrument is informative for symptom management
because it estimates functional status, comorbid conditions, cognitive status, mental and
social health, nutritional state, and polypharmacy.4,5 More research is needed with OWBC
to identify better models for predicting slower recovery time and to determine if
rehabilitation between the time of diagnosis and start of acute treatment minimizes
declines.21
Similar to Ganz,6 Prescott,7 and smaller studies,11,20 we observed comparable HRQOL
changes when comparing treatment types, suggesting that other variables play a greater role
in OWBC's HRQOL outcomes. For instance, in Alberg and Singh's conceptual model of
aging and treatment for breast cancer, comorbid conditions assume the central role.2 The
length of time women have comorbid conditions may affect HRQOL in important ways but
we were not able to determine this from our data. In analyses, we controlled for comorbid
conditions present at baseline and conditions developed between baseline and follow-up.
The interrelationships between breast cancer and comorbid conditions are not well
understood in OWBC and the mechanisms by which they affect HRQOL and recovery time
need to be elucidated.
Our study builds on the population-based findings of Prescott7 and Ganz6 by including
assessments prior to diagnosis, more geographic sites in the U.S. (14 vs. 4 in Ganz6), and a
matched-control group of older women without breast cancer. We used propensity score
matching to select the most appropriate controls for each breast cancer case, which reduces
bias by balancing demographic characteristics and comorbid conditions between cancer and
no-cancer groups.10
Finally, our results are also consistent with research showing initial declines and then
improvement in HRQOL scores from 6-18 months post-diagnosis for younger pre-
menopausal and middle-aged women with early stage breast cancer.22 Unfortunately,
extrapolating guidelines for treating OWBC from research conducted with younger women
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is not clinically indicated because OWBC have different pathology, clinical, and
psychological profiles. OWBC are less likely to be node-positive, have smaller and slower
growing tumors, greater comorbid conditions, more interactions with medications, and less
psychological impact from cancer than younger women.2,5 It is imperative that OWBC be
included in clinical trials and prospective observational studies of HRQOL (in sufficient
numbers to meet a priori power requirements for sub-analyses) to better understand HRQOL
outcomes and recovery time across a range of treatment situations.
Limitations
Dataset limitations are important to consider when interpreting these findings. SEER
limitations may have led to misclassification of treatment types. MHOS limitations include a
modified HRQOL measure administered to later cohorts and a lack of cancer-specific
HRQOL variables. We consider each of these in turn.
Radiation therapy received beyond 6 months post-diagnosis is not captured well in SEER,23
which may have led to misclassification of treatment types. Radiation therapy involves
treatment five days a week for 3-7 weeks. The median time from surgery to initiation of
radiation is 34 days,24 suggesting that the lack of this data beyond six months after diagnosis
had minimal impact on our data.
SEER reports only the most invasive surgery so it was not possible to identify OWBC who
first received BCS and received a mastectomy later.25 We also were not able to form a no-
surgery group because this has not been validated in SEER,25 nor groups for reconstructive
surgery because the sample size would have been too low to produce reliable estimates.
Given that women in our sample were enrolled in managed care plans, we also did not have
access to claims information. All of these situations are important to understand for better
treatment management in OWBC.
MHOS dataset limitations include different versions of the SF-36/VR-12 items being
administered for follow-up in cohorts 7-8. Only 13-14% of follow-up scores were affected
by this change in both cancer and no-cancer groups. We used published algorithms to create
variables that were directly comparable for SF-36/VR-12.14 Cohort year was reflected in
propensity scores and controlled for in analyses. The MHOS also lacks variables assessing
body mass index and cancer-specific HRQOL variables such as bowel functioning, sexual
functioning, cognitive functioning, and body image.9 These would be important variables to
consider in future research with OWBC.
Conclusions
Women ages 65 years and older diagnosed with breast cancer should be counseled that
treated survivors within 6 months of diagnosis are particularly vulnerable to declines in
HRQOL, as compared to older women without breast cancer, but that these decrements
generally wane after 12 months. This should be reassuring to older breast cancer patients
who are frequently in good health otherwise with relatively long life expectancies. Our
findings also suggest that enhanced symptom monitoring may be warranted for older women
during treatment. Careful attention to the management of treatment-related symptoms may
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shorten recovery time to usual functioning among OWBC, especially during the first 6
months after diagnosis.
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Figure 1. Selection of Older Women with and without Breast Cancer
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Figure 2. VR-12 Subscale Score Changes and 95% Confidence Intervals for Older Women with
and without Breast Cancer: Time Since Diagnosis
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Figure 3. VR-12 Subscale Score Changes and 95% Confidence Intervals for Older Women with
and without Breast Cancer: Treatment Types
Stover et al. Page 13































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cancer. Author manuscript; available in PMC 2015 June 15.
